Drug
Alefacept clinical trials
Also written Amevive and ASP0485.
- studies test it
- 32
- open now
- 0
- in phase 3
- 5
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2008 (6)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 5
- Phase 4
- 7
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 20
Astellas Pharma Inc (10) · Hadassah Medical Organization (2) · Biogen (1) · Mayo Clinic (1) · University of Minnesota (1) · University of California, San Francisco (1) · Wake Forest University (1) · Rush University Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Alefacept is read from its arms, and is right about nine times in ten.
Testing it · 32
- Safety and Tolerability of Repeat Courses of IM AlefaceptCompletedPhase 3BiogenNCT00233662Written as Alefacept
- Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's LymphomaCompletedPhase 1Mayo ClinicNCT00438802Written as Alefacept
- Alefacept in Patients With Severe Scalp Alopecia AreataCompletedNot applicableUniversity of MinnesotaNCT00167102Written as Alefacept
- Open Label Study of Alefacept Injections to Patients With Moderate to Severe PsoriasisCompletedNot applicableUniversity of California, San FranciscoNCT00678470Written as Intralesional Alefacept
- Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type PsoriasisCompletedPhase 4Wake Forest UniversityNCT00655564Written as Alefacept
- A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra PilarisTerminatedPhase 4Joshua ZeichnerNCT00815633Written as Alefacept
- Alefacept in Patients With Relapsed/Refractory Aplastic AnemiaTerminatedPhase 1The Cleveland ClinicNCT01267643Written as Alefacept
- Alefacept and Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNot applicableEmory UniversityNCT01319851Written as Alefacept
- Inducing Remission in Type 1 Diabetes With AlefaceptTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00965458Written as Alefacept
- A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant RecipientsCompletedPhase 2Astellas Pharma IncNCT00617604Written as Alefacept
- A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant RecipientsCompletedPhase 2Astellas Pharma IncNCT00543569Written as Alefacept
- Alefacept for Chronic Graft Versus Host DiseaseCompletedPhase 1/2Hadassah Medical OrganizationNCT00397332Written as Alefacept
- Alefacept for Prevention of Graft Versus Host Disease (GVHD)TerminatedPhase 3Hadassah Medical OrganizationNCT00361413Written as Alefacept (AMEVIVE®)
- Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque PsoriasisCompletedPhase 3Astellas Pharma IncNCT00692172Written as Alefacept
- A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic ArthritisCompletedPhase 2Astellas Pharma IncNCT00659412Written as Alefacept
- Community Based Trial for AMEVIVE®CompletedPhase 4Astellas Pharma IncNCT00168753Written as Alefacept
- A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3Astellas Pharma IncNCT00674063Written as alefacept
- A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or InappropriateCompletedPhase 3Astellas Pharma IncNCT00673556Written as alefacept
- Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe PsoriasisCompletedPhase 2Astellas Pharma IncNCT00808223Written as alefacept
- Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host DiseaseTerminatedPhase 2Dana-Farber Cancer InstituteNCT01226420Written as Alefacept
See all 32 studies that test Alefacept →
As the comparator · 1 — what is tested is compared with Alefacept
Codes
What other systems call Alefacept · ClinicalTrials.gg INT006815
- MeSH (NLM) D000077944AlefaceptConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ELK3V90G6CALEFACEPTConfirmed FDA, NLM, Wikidata
- RxNorm 299635Confirmed FDA, Wikidata
- Wikidata Q3609421alefaceptConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65220AlefaceptOne source FDA
- DrugBank DB00092One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077944 | Alefacept | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ELK3V90G6C | ALEFACEPT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 299635 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3609421 | alefacept | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65220 | Alefacept | One source FDA |
| DrugBank | DB00092 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.